There are 599 papers on gastric cancer in aging research: 31 trials and 343 observational studies in people, 10 in animals, 11 in cells, 142 reviews.
599 papers study it159 more mention it205 findings
50 new papers in 30 daysSee all 758 papers on gastric cancer
“In the SIT dataset, after 29.4 years of follow-up, H. pylori treatment was associated with a 34% reduction in GC incidence (HR = 0.66, 95% CI 0.46–0.95).”
- Human trial31
- Humans343
- Animals10
- Cells11
- In silico60
Interventions
13Vitamin B12
no changein humans1OR 1.04
1 study
Vitamin B12
no changein humans1OR 1.04
Vitamin B12 showed no clear effect on gastric cancer in humans (OR 1.04, 95% CI 0.99–1.10 per quartile of intake).
“Overall, dietary vitamin B12 intake was not associated with gastric cancer risk”
Reviewper quartile of dietary intake
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
Metformin
no changein humans1
1 study
Metformin
no changein humans1
Metformin showed no clear effect on gastric cancer in humans (type 2 diabetes; short-term use).
“short-term use (< 3 years) did not show a significant benefit.”
Reviewtype 2 diabetes; short-term use< 3 years
Metformin use and the risk of gastric cancer: a systematic review and meta-analysis
Research SquarePreprint
Seafood
no changein humans1
1 study
Seafood
no changein humans1
Seafood was not clearly linked with gastric cancer in humans.
“no association was found for unprocessed red meat, poultry, or seafood.”
Humans
International journal of epidemiology
Poultry
no changein humans1
1 study
Poultry
no changein humans1
Poultry was not clearly linked with gastric cancer in humans.
“no association was found for unprocessed red meat, poultry, or seafood.”
Humans
International journal of epidemiology
Unprocessed red meat
no changein humans1
1 study
Unprocessed red meat
no changein humans1
Unprocessed red meat was not clearly linked with gastric cancer in humans.
“no association was found for unprocessed red meat, poultry, or seafood.”
Humans
International journal of epidemiology
Riboflavin
no changein humans1OR 0.97
1 study
Riboflavin
no changein humans1OR 0.97
Riboflavin was not clearly linked with gastric cancer in humans (per one-quartile increase in intake) (OR=0.97 (95% CI = 0.93-1.02)).
“B2, OR=0.97 (95% CI = 0.93-1.02)”
Humansper one-quartile increase in intake
European journal of nutrition
Helicobacter pylori eradication
downin humans1
1 study
Helicobacter pylori eradication
downin humans1
Helicobacter pylori eradication prevents gastric cancer in humans (even in the presence of dysplasia or early GC).
“H. pylori eradication can prevent future GC incidence, even in the presence of dysplasia or early GC”
Revieweven in the presence of dysplasia or early GC
Expert review of gastroenterology & hepatology
Gastric cancer screening
no changein humans1
1 study
Gastric cancer screening
no changein humans1
Gastric cancer screening was not clearly linked with gastric cancer in humans (P for trend = 0.079).
“Screening compliance was not significantly associated with ETI or gastric cancer incidence.”
Humans8.2 yearsn = 2,394,562
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
Pro-inflammatory diet
no changein humans1
1 study
Pro-inflammatory diet
no changein humans1
Pro-inflammatory diet showed no clear effect on gastric cancer in humans (cohort studies).
“No significant associations were found for gastric or pancreatic cancers in cohort studies.”
Reviewcohort studies
BMC cancer
Nortriptyline
downin humans1
1 study
Nortriptyline
downin humans1
Nortriptyline decreases gastric cancer in gastric cancer models.
“Nor administration attenuates lysosomal exocytosis-mediated senescence-associated secretory phenotype (SASP) and reduces aggressive phenotypes in gastric cancer models”
Animalsin gastric cancer models
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
All 13Fewer
Effects
4Deaths
upin humans1
1 study
Deaths
upin humans1
Gastric cancer is linked with higher deaths in humans (1990 to 2021 global absolute burden).
“Compared to 1990, the number of GC cases and deaths increased in 2021”
Humans1990 to 2021 global absolute burdenstomach1990 to 2021
Medicine
Age-standardized mortality rate
downin humans1
1 study
Age-standardized mortality rate
downin humans1
Gastric cancer is linked with lower age-standardized mortality rate in humans (1990 to 2021 global trend).
“meanwhile, the age-standardized incidence rate, age-standardized mortality rate, and age-standardized disability-adjusted life years rate declined, respectively.”
Humans1990 to 2021 global trendstomach1990 to 2021
Medicine
GSTM2
downin human cells1
1 study
GSTM2
downin human cells1
Gastric cancer decreases GSTM2 in human cells (GC cell lines).
“showing high expression of CCNB1, NUF2, and THBS2 and low expression of GSTM2 in GC cell lines”
CellsGC cell lines
Translational cancer research
CCNB1
upin human cells1
1 study
CCNB1
upin human cells1
Gastric cancer increases CCNB1 in human cells (GC cell lines).
“showing high expression of CCNB1, NUF2, and THBS2 and low expression of GSTM2 in GC cell lines”
CellsGC cell lines
Translational cancer research
Upstream
8Jiangsu Province cancer registry data (2010-2021)
downin humans1
1 study
Jiangsu Province cancer registry data (2010-2021)
downin humans1
Jiangsu Province cancer registry data (2010-2021) is linked with lower gastric cancer in humans.
“age-standardized incidence and mortality declined for esophageal, gastric, and liver cancer”
Humans2010-2021
Trends and future burden of major digestive system cancers in Jiangsu Province, China, 2010-2030
Frontiers in oncology
New GC instances
upin humans1
1 study
New GC instances
upin humans1
New GC instances are linked with higher gastric cancer in humans (nearly twofold increase).
“From 1990 to 2021, Iran saw nearly a twofold increase in new GC instances”
Humansstomach1990 to 2021
Journal of gastrointestinal cancer
Age-standardized incidence rate
downin humans1
1 study
Age-standardized incidence rate
downin humans1
Age-standardized incidence rate is linked with lower gastric cancer in humans (from 23.12 to 14.37 per 100,000).
“however, the age-standardized incidence rate (ASIR) significantly fell from 23.12 to 14.37 per 100,000 individuals.”
Humansstomach1990 to 2021
Journal of gastrointestinal cancer
MMP12
downin human cells1
1 study
MMP12
downin human cells1
MMP12 protects against gastric cancer in GC cells.
“cellular experiments demonstrated that the MMP12 gene serves as a protective factor in GC cells.”
Cellsin GC cells
International immunopharmacology
Parkinson's disease
no changein humans1OR 0.94
1 study
Parkinson's disease
no changein humans1OR 0.94
Parkinson's disease was not clearly linked with gastric cancer in humans (Genetically predicted Parkinson's disease) (OR 0.94, 95% CI 0.89–0.99; P=0.22; reported interval conflicts with the null conclusion and P-value).
“As for GC, no causal effect was found (OR =0.94, 95% CI: 0.89-0.99; P=0.22).”
HumansGenetically predicted Parkinson's disease
Journal of gastrointestinal oncology
Anti-intrinsic factor antibodies
no changein humans1
1 study
Anti-intrinsic factor antibodies
no changein humans1
Anti-intrinsic factor antibodies were not clearly linked with gastric cancer in humans.
“In both cohorts, anti-intrinsic factor antibody seroprevalence was less than 2% among cases as well as controls and not statistically associated with GC risk.”
Humansstomach
Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies With Risk of Gastric Cancer
JAMA oncology
Antiparietal cell antibodies
no changein humans1OR 0.99
1 study
Antiparietal cell antibodies
no changein humans1OR 0.99
Antiparietal cell antibodies were not clearly linked with gastric cancer in H pylori-seronegative men (OR 0.99, 95% CI 0.32-3.04).
“In the ATBC Study, APCA seropositivity was not associated with GC among either H pylori-seronegative men (OR, 0.99; 95% CI, 0.32-3.04)”
Humansin H pylori-seronegative menstomachmales
Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies With Risk of Gastric Cancer
JAMA oncology
Triglyceride
no changein humans1
1 study
Triglyceride
no changein humans1
Triglyceride was not clearly linked with gastric cancer in humans.
“Triglyceride was not independently related with gastric cancer risk among both pre- and postmenopausal women.”
Humansmean 8.26 yearsfemales
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Associations
154Helicobacter pylori eradication
downin humans5HR 0.44–0.66
5 studies
Helicobacter pylori eradication
downin humans5HR 0.44–0.66
Helicobacter pylori eradication lowers the risk of gastric cancer (HR 0.66, 95% CI 0.46–0.95).
“In the SIT dataset, after 29.4 years of follow-up, H. pylori treatment was associated with a 34% reduction in GC incidence (HR = 0.66, 95% CI 0.46–0.95).”
Human trial29.4 yearsn = 1,811
Genetic score may help target stomach cancer prevention
Innovation (Cambridge (Mass.))
Helicobacter pylori eradication lowers the risk of gastric cancer in humans (MITS; high-treatment-benefit individuals identified using PTBS) (HR 0.44, 95% CI 0.35–0.54; NNT 56).
“With the PTBS, targeting the high-treatment-benefit individuals conferred stronger protection against GC”
Human trialMITS; high-treatment-benefit individuals identified using PTBSn = 1,740
Genetic score may help target stomach cancer prevention
Innovation (Cambridge (Mass.))
Helicobacter pylori eradication is linked with a lower risk of gastric cancer in humans (SIR 0.56 (95% CI, 0.52-0.61) in 70-74 age group).
“GC incidence and mortality rates were significantly lower in H pylori-treated individuals than in the general population across all age-groups”
Humans
Gastroenterology
Helicobacter pylori eradication lowers the risk of gastric cancer in humans.
“Helicobacter pylori eradication reduces subsequent gastric cancer risk”
Review
Clinical and experimental gastroenterology
Helicobacter pylori eradication lowers the risk of gastric cancer in humans (combined with risk-stratified screening).
“Population-wide Helicobacter pylori eradication combined with risk-stratified screening represents an effective strategy to reduce gastric cancer burden.”
Reviewcombined with risk-stratified screening
Infection-driven cancers in Asia: implications from epidemiological transitions
The Lancet regional health. Western Pacific
Helicobacter pylori eradication lowers the risk of gastric cancer in humans (high-risk areas).
“Large-scale randomized controlled intervention trials in high-risk areas have provided robust evidence to support H. pylori eradication as an effective primary prevention strategy.”
Reviewhigh-risk areas
Gastric cancer in China: Epidemiology, risk factors, and screening
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Metformin
downin humans3HR 0.448–0.72
3 studies
Metformin
downin humans3HR 0.448–0.72
Metformin is linked with a lower risk of gastric cancer in humans (Genetically instrumented metformin treatment) (OR <0.1; P <.05).
“inverse-variance weighting estimates demonstrated a protective effect of metformin against esophageal, gastric, and colorectal cancers (all odds ratios <0.1, all P <.05).”
HumansGenetically instrumented metformin treatment
Medicine
Metformin is linked with a lower risk of gastric cancer in patients with type 2 diabetes (HR 0.448, 95% CI 0.359-0.558).
“The overall hazard ratio (95% confidence intervals) of 0.448 (0.359-0.558) suggested a significantly lower risk among ever users.”
Humansin patients with type 2 diabetes
Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus
Aging
Metformin is associated with gastric cancer in humans (type 2 diabetes) (HR 0.72, 95% CI 0.39–0.87).
“metformin use was associated with a significant reduction in the risk of gastric cancer (HR = 0.72; 95% CI: 0.39–0.87; P = 0.0008).”
Reviewtype 2 diabetes
Metformin use and the risk of gastric cancer: a systematic review and meta-analysis
Research SquarePreprint
Helicobacter pylori
upin humans3HR 2.03
3 studies
Helicobacter pylori
upin humans3HR 2.03
Helicobacter pylori is linked with a higher risk of gastric cancer in humans (HR 2.03, 95% CI: 1.25-3.26).
“H. pylori-associated atrophic gastritis (HPAG) was significantly associated with increased risks of gastric cancer (HR 2.03; 95% CI: 1.25-3.26; p = 0.012)”
Humansn = 1,252
Asian Pacific journal of cancer prevention : APJCP
Helicobacter pylori raises the risk of gastric cancer in humans.
“The literature review highlighted Helicobacter pylori infection as the predominant risk factor”
Reviewstomach
Gastric cancer burden, risk factors, and early detection strategies in Latin America and Colombia
Research SquarePreprint
Helicobacter pylori raises the risk of gastric cancer in humans (H. pylori infection).
“Furthermore, H. pylori induces cellular senescence and promotes atrophy progression and finally increases the gastric cancer risk.”
ReviewH. pylori infection
Frontiers in medicine
Smoking
upin humans3
3 studies
Smoking
upin humans3
Smoking is linked with a higher risk of gastric cancer in humans.
“Smoking remained the leading attributable risk factor, particularly in China.”
Humans
Discover oncology
Smoking is associated with gastric cancer in humans.
“Smoking, high sodium intake, and high alcohol use together accounted for a substantial but shrinking age-standardized share of GC deaths and DALYs.”
Humans
Gastric Cancer in China, 1990 to 2023: Trends, Modifiable Risks, and Prevention Priorities
Journal of clinical gastroenterology
Smoking is linked with a higher risk of gastric cancer in humans (young adults) (p < 0.001).
“Multiple risk factorswere significantly associated with PGLs and EOGC, including H. pylori infection (p = 0.022), increasing age (p < 0.001), a family history of gastric cancer (p < 0.001), poor dietary habits (p < 0.001), obesity (p < 0.001), and smoking (p < 0.001).”
Humansyoung adults
Current oncology (Toronto, Ont.)
OLGIM
upin humans2RR 12.38
2 studies
OLGIM
upin humans2RR 12.38
OLGIM is associated with gastric cancer in humans (OLGIM stages III-IV compared with stages 0-II) (RR 12.38).
“stages III-IV were associated with substantially higher risks of gastric cancer than stages 0-II, with risk ratios of 32.31 and 12.38, respectively.”
ReviewOLGIM stages III-IV compared with stages 0-II
Clinical and experimental gastroenterology
OLGIM is associated with gastric cancer in humans (Observational studies; OLGIM stage II) (OR 3.63; 95% CI 2.90–4.55).
“and OLGIM II (OR 3.63; 95% CI 2.90-4.55; I2 = 0%).”
ReviewObservational studies; OLGIM stage II
Helicobacter
OLGA
upin humans2RR 32.31
2 studies
OLGA
upin humans2RR 32.31
OLGA is associated with gastric cancer in humans (OLGA stages III-IV compared with stages 0-II) (RR 32.31).
“stages III-IV were associated with substantially higher risks of gastric cancer than stages 0-II, with risk ratios of 32.31 and 12.38, respectively.”
ReviewOLGA stages III-IV compared with stages 0-II
Clinical and experimental gastroenterology
OLGA is associated with gastric cancer in humans (Observational studies; OLGA stage II) (OR 2.77; 95% CI 1.83–4.20).
“Intermediate stages were also associated with GC in observational studies: OLGA II (OR 2.77; 95% CI 1.83-4.20; I2 = 71%)”
ReviewObservational studies; OLGA stage II
Helicobacter
Helicobacter pylori infection
upin humans2
2 studies
Helicobacter pylori infection
upin humans2
Helicobacter pylori infection raises the risk of gastric cancer in humans.
“Helicobacter pylori is a major causal factor, but mucosal damage, hereditary susceptibility, and other exposures affect risk.”
Review
Journal of clinical medicine
Helicobacter pylori infection raises the risk of gastric cancer in humans (Helicobacter pylori infection).
“Helicobacter pylori (H. pylori) infection is chronic and etiologically linked to gastric cancer (GC) derived from gastric epithelium.”
ReviewHelicobacter pylori infection
Detection and Treatment of Helicobacter pylori: Problems and Advances
Gastroenterology research and practice
Alcohol-related liver disease
upin humans2HR 1.4
2 studies
Alcohol-related liver disease
upin humans2HR 1.4
Alcohol-related liver disease is linked with a higher risk of gastric cancer in humans (IRR 2.41).
“ALD was associated with an elevated risk of esophageal cancer (IRR, 5.98) and stomach cancer (IRR, 2.41)”
Humansn = 43,994
Gut and liver
Alcohol-related liver disease is linked with a higher risk of gastric cancer in humans (cohort of 362,285 individuals) (HR 1.40 (95% CI: 1.16-1.68)).
“and 1.40 (1.16-1.68) for ALD.”
Humanscohort of 362,285 individualsn = 362,285
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Microbiome composition
upin humans2
2 studies
Microbiome composition
upin humans2
Microbiome composition predicts gastric cancer in humans (training set) (AUC 0.96, 0.87, and 0.96).
“AUC values in the training set reached 0.96, 0.87, and 0.96 for oral, gastric fluid and gastric mucosa classifiers respectively”
Humanstraining set
Journal of translational medicine
Microbiome composition raises the risk of gastric cancer in gastric carcinogenesis.
“gastric microbiome including Helicobacter pylori and diverse non-H. pylori bacteria, fungi, and viruses actively contribute to gastric carcinogenesis”
Reviewin gastric carcinogenesis
Probiotics and antimicrobial proteins
Helicobacter pylori
upin humans2
2 studies
Helicobacter pylori
upin humans2
Helicobacter pylori raises the risk of gastric cancer in Korean diaspora populations.
“gastric cancer risk in Korean migrants reflects the interaction of pre-migration exposures, host susceptibility, and post-migration environmental change.”
Reviewin Korean diaspora populations
Preprints.orgPreprint
Helicobacter pylori raises the risk of gastric cancer in humans (infection) (PARP 23.66%).
“For PARP were 34.22% (pickled food), 34.24% (edible hot food) and 23.66%(H. pylori infection).”
Reviewinfection
Aging
All 154Fewer
Trial sponsors
Company19 trialsPhase 44,881 people
Company12 trialsPhase 36,608 people
Company5 trialsPhase 32,932 people
Company5 trialsPhase 31,843 people
Company5 trialsPhase 31,360 people
Company4 trialsPhase 3732 people
Company3 trialsPhase 31,928 people
Jiangsu Hengrui Pharmaceuticals
Company3 trialsPhase 31,502 people
Funding
25 grants since 2016National Cancer Institute$23MJapan Society for the Promotion of Science¥29.1MNational Institute of Diabetes and Digestive and Kidney Diseases$838K
National Cancer InstituteStanford University$1.8M2023–2028
Comparative Modeling of Gastric Cancer Prevention, Screening, and Surveillance in the US
National Cancer InstituteColumbia University Health Sciences$1.2M2026–2031
National Cancer InstituteDuke University$12.6K2022–2027
National Cancer InstituteSloan-kettering Inst Can Research$89.5K2024–2029
National Cancer InstituteBaylor College of Medicine$663K2026–2031
Japan Society for the Promotion of ScienceKawasaki Medical School¥4.3M2026–2029
Japan Society for the Promotion of ScienceMiyagi Prefectural Hospital Organization¥4.6M2026–2030
Assessing feasibility of gastric cancer screening in the US
National Cancer InstituteCleveland Clinic Lerner Com-cwru$539K2025–2030
Comparative modeling of gastric cancer health drivers and prevention in the US and globally
National Cancer InstituteColumbia University Health Sciences$899K2021–2027
Early Detection and Interception of Diffuse and Intestinal Gastric Cancer